[The plasma levels and diagnostic utility of selected hematopoietic growth factors in endometrial cancer patients and with myoma uteri].
Hematopoietic growth factors (HGFs) are involved in the regulation of growth hematopoietic cells. Some clinical investigations have shown an autologous production of HGFs in various human cell lines in vitro and by tumour cells in vivo, for example in endometrial cancer. To evaluate the plasma levels and diagnostics utility of selected HGFs, such as SCF M-CSF, G-CSF in endometrial cancer patients and with myoma uteri. We have investigated the plasma levels of HGFs and tumor marker like CA 125 in patients with endometrial cancer (55 women), with myoma uteri (30 patients) and in 30 healthy subjects. HGFs were determined using enzyme-linked immunosorbent assay (ELISA), CA 125 was measured by chemiluminescence immunoassay (CMIA). SCF and M-CSF similarly to CA 125 plasma levels were significantly higher in endometrial cancer patients comparing to the healthy subjects. Furthermore M-CSF was significantly higher in endometrial cancer comparing to the myoma patients. The diagnostic sensitivity of M-CSF was high and slightly lower than CA 125 (51% and 60% respectively). The combined use of all tested cytokines resulted in the increased sensitivity range, especially with marker CA 125 (84%). Diagnostic specificities were high and equal for all tested cytokines and for CA 125(93%). Positive predictive values (PPV) were high for all tested parameters, and negative predictive values (NPV) were higher enough to exclude endometrial cancer. Our study suggest that tested cytokines (HGFs) can be clinically useful in diagnostic of endometrial cancer patients. M-CSF can be clinically useful in differentiation of endometrial cancer and myoma uteri. Furthermore SCF and M-CSF showed usefulness in primary diagnostic of cancer uteri, especially with CA 125.